• Clinical Success: Apitegromab plus standard of care delivered a 1.8-point improvement compared to placebo in the SMA-specific Hammersmith functional motor scale at week 52.
• Patient Improvement: 30% of patients achieved an additional 3-point or greater improvement in Hammersmith scores compared to 12.5% with placebo plus SMN therapy.
• Safety Profile: Safety consistent with TOPAZ data; over 95% of patients rolled over and remained in long-term follow-up study.
• Market Potential: Approximately two-thirds of 10,000 SMA patients in the US and 35,000 globally have received SMN-targeted therapy.
• Commercial Preparation: Scaling customer-facing team to roughly 50 personnel in late Q2 and early Q3 for potential Q4 launch.
• Cardiometabolic Program: Top-line data from EMBRAZE expected in Q2; IND filing for SRK439 in Q3.
• Lean Muscle Preservation: Aim to reduce lean muscle mass loss by 20% to 40% in EMBRAZE study.
• Regulatory Milestones: BLA for apitegromab submitted in the US in January; MAA submission in the EU on track for March.

• Warning! GuruFocus has detected 2 Warning Sign with SRRK.

Release Date: February 27, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

• Scholar Rock Holding Corp (NASDAQ:SRRK) is on track to launch apitegromab, a muscle-targeted therapy for SMA, in the US in 2025, with plans to expand to the EU in 2026.
• The SAPPHIRE study showed that apitegromab plus standard of care delivered clinically meaningful and statistically significant improvements in motor function for SMA patients.
• The company is making significant progress in its cardiometabolic program, with plans to share top-line data from the EMBRAZE study in Q2 2025.
• Scholar Rock Holding Corp (NASDAQ:SRRK) has a strong commercial strategy, including the 'Life Takes Muscle' campaign, to prepare the market for the new treatment paradigm in SMA.
• The company is actively engaging with payers and stakeholders to ensure access and coverage for apitegromab, reflecting its value in treating SMA.

Negative Points

• There is still uncertainty around the regulatory acceptance of body composition changes as a primary endpoint for the cardiometabolic program.
• The competitive landscape for weight loss therapies is intensifying, which may impact the commercial success of SRK-439.
• The company has not yet disclosed pricing details for apitegromab, which could affect market acceptance and payer negotiations.
• The development of additional neuromuscular indications for apitegromab is still in the early stages, with no specific timelines provided.
• The potential impact of preserving lean muscle mass on overall weight loss with GLP-1 receptor therapies remains uncertain, which could affect the perceived value of SRK-439.

Q & A Highlights

Q: With the SAPPHIRE data being presented at the MDA conference, what additional data points will be most meaningful to patients and doctors? Also, regarding obesity, what do you need to see on the primary endpoint to confidently advance SRK-439? A: Jay Backstrom, President and CEO, emphasized the importance of the overall consistency and impact of the SAPPHIRE data across age groups. For the EMBRAZE study and SRK-439, a 20% to 40% improvement in lean mass is considered clinically meaningful. The focus is on demonstrating a significant effect on lean mass, which will guide the development of SRK-439.

Q: Regarding the obesity readout, how do you expect the biology to affect actual weight loss, considering the preservation of lean muscle? A: Jay Backstrom explained that at week 24, the weight loss is expected to be comparable between the two arms due to the significant weight loss already occurring with tirzepatide. However, over time, there is potential for additional incremental weight loss due to the effects on basal metabolic rate and muscle preservation.

Q: How should we think about exploring additional neuromuscular indications for apitegromab, and how will you allocate capital while ensuring proper investment in SMA launches? A: Jay Backstrom stated that Scholar Rock is actively exploring adjacent neuromuscular indications like DMD, FSHD, Becker's, and ALS. The company is engaging with experts and using translational models to assess opportunities. Scholar Rock is positioned to take on additional clinical studies while focusing on the SMA launch.

Q: With the FDA's draft guidance on obesity clinical trials focusing on BMI and weight loss, what are the implications for your cardiometabolic program, particularly SRK-439? A: Jay Backstrom noted that the FDA's guidance reinforces the importance of assessing lean mass loss. Scholar Rock plans to demonstrate additional benefits from SRK-439, such as metabolic improvements and functional measures, which could be regulatory approval endpoints.

Q: If EMBRAZE achieves 1 to 2 kilograms of lean mass preservation with apitegromab, how might SRK-439 perform, and what are your thoughts on pricing for SMA treatments? A: Jay Backstrom highlighted that SRK-439 is designed to have a low-dose subcutaneous formulation, which is advantageous in a competitive space. Tracey Sacco, Chief Commercial Officer, mentioned that payers are receptive to the innovation of muscle-targeted therapy in SMA, and pricing will reflect the value apitegromab brings to the market.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.